Mainz Biomed N.V.
QUCY
$0.43
-$0.03-6.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.90% | -32.90% | -44.93% | -44.93% | -13.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.90% | -32.90% | -44.93% | -44.93% | -13.13% |
| Cost of Revenue | -57.24% | -57.24% | -51.83% | -51.83% | -26.63% |
| Gross Profit | -21.74% | -21.74% | -40.56% | -40.56% | -5.05% |
| SG&A Expenses | -41.68% | -41.68% | -24.09% | -24.09% | -32.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.57% | -37.57% | -18.88% | -18.88% | -33.42% |
| Operating Income | 37.77% | 37.77% | 17.50% | 17.50% | 34.08% |
| Income Before Tax | 25.61% | 25.61% | 24.31% | 24.31% | -2.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.61% | 25.61% | 24.31% | 24.31% | -2.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.61% | 25.61% | 24.31% | 24.31% | -2.01% |
| EBIT | 37.77% | 37.77% | 17.50% | 17.50% | 34.08% |
| EBITDA | 39.46% | 39.46% | 16.83% | 16.83% | 32.80% |
| EPS Basic | 88.12% | 88.12% | 86.55% | 86.55% | 65.54% |
| Normalized Basic EPS | 90.87% | 90.87% | 85.84% | 85.84% | 74.64% |
| EPS Diluted | 88.12% | 88.12% | 86.55% | 86.55% | 65.54% |
| Normalized Diluted EPS | 90.87% | 90.87% | 85.84% | 85.84% | 74.64% |
| Average Basic Shares Outstanding | 526.42% | 526.42% | 462.71% | 462.71% | 196.04% |
| Average Diluted Shares Outstanding | 526.42% | 526.42% | 462.71% | 462.71% | 196.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |